KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Paul K. Audhya Sells 2,394 Shares of Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul K. Audhya sold 2,394 shares of KalVista Pharmaceuticals stock in a transaction on Monday, February 24th. The stock was sold at an average price of $10.02, for a total transaction of $23,987.88. Following the sale, the insider now directly owns 102,940 shares in the company, valued at approximately $1,031,458.80. This trade represents a 2.27 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

KalVista Pharmaceuticals Trading Up 4.1 %

Shares of KALV opened at $10.77 on Wednesday. The firm has a market cap of $532.23 million, a P/E ratio of -2.96 and a beta of 0.85. KalVista Pharmaceuticals, Inc. has a 12-month low of $7.30 and a 12-month high of $15.50. The company’s 50-day moving average price is $8.94 and its 200 day moving average price is $10.35.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings data on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.01. Equities research analysts forecast that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. TD Cowen assumed coverage on shares of KalVista Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating and a $30.00 price target on the stock. Bank of America assumed coverage on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 18th. They set a “buy” rating and a $22.00 price target on the stock. Needham & Company LLC reissued a “buy” rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a research report on Thursday, December 5th. Citizens Jmp raised shares of KalVista Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 31st. Finally, JMP Securities assumed coverage on shares of KalVista Pharmaceuticals in a research report on Friday, January 31st. They set an “outperform” rating and a $19.00 price target on the stock. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $23.80.

Institutional Trading of KalVista Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of KALV. State Street Corp grew its position in shares of KalVista Pharmaceuticals by 68.1% during the third quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company’s stock worth $14,725,000 after buying an additional 515,179 shares in the last quarter. Hennion & Walsh Asset Management Inc. acquired a new position in KalVista Pharmaceuticals in the fourth quarter valued at approximately $634,000. Vestal Point Capital LP boosted its holdings in KalVista Pharmaceuticals by 73.9% in the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the specialty pharmaceutical company’s stock valued at $46,320,000 after purchasing an additional 1,700,000 shares in the last quarter. Barclays PLC boosted its holdings in KalVista Pharmaceuticals by 418.5% in the third quarter. Barclays PLC now owns 67,222 shares of the specialty pharmaceutical company’s stock valued at $778,000 after purchasing an additional 54,257 shares in the last quarter. Finally, Readystate Asset Management LP acquired a new position in KalVista Pharmaceuticals in the third quarter valued at approximately $2,084,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).